Background: Video-assisted thoracic surgery (VATS) emerged as a minimally invasive surgery for diseases in the field of thoracic surgery. We herein reviewed our experience on thoracoscopic lobectomy for early lung cancer and evaluated Health System use.

Methods: A cost-effectiveness study was performed comparing VATS vs. open thoracic surgery (OPEN) for lung cancer patients. Demographic data, tumor localization, dynamic pulmonary function tests [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), diffusion capacity (DLCO) and maximal oxygen uptake (VO2max)], surgical approach, postoperative details, and complications were recorded and analyzed.

Results: One hundred seventeen patients underwent lung resection by VATS (n=42, 36%; age: 63±9 years old, 57% males) or OPEN (n=75, 64%; age: 61±11 years old, 73% males). Pulmonary function tests decreased just after surgery with a parallel increasing tendency during first 12 months. VATS group tended to recover FEV1 and FVC quicker with significantly less clinical and post-surgical complications (31% 53%, P=0.015). Costs including surgery and associated hospital stay, complications and costs in the 12 months after surgery were significantly lower for VATS (P<0.05).

Conclusions: The VATS approach surgery allowed earlier recovery at a lower cost than OPEN with a better cost-effectiveness profile.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594203PMC
http://dx.doi.org/10.21037/jtd.2017.07.51DOI Listing

Publication Analysis

Top Keywords

thoracic surgery
16
lung cancer
12
video-assisted thoracic
8
surgery
8
pulmonary function
8
function tests
8
lung
5
vats
5
cost effectiveness
4
effectiveness lung
4

Similar Publications

Impact of Inflammation After Cardiac Surgery on 30-Day Mortality and Machine Learning Risk Prediction.

J Cardiothorac Vasc Anesth

December 2024

Division of Cardiac Surgery, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; Division of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, Bari, Italy. Electronic address:

Objectives: To investigate the impact of systemic inflammatory response syndrome (SIRS) on 30-day mortality following cardiac surgery and develop a machine learning model to predict SIRS.

Design: Retrospective cohort study.

Setting: Single tertiary care hospital.

View Article and Find Full Text PDF

Corrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].

Cancer Lett

December 2024

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong; Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong. Electronic address:

View Article and Find Full Text PDF

Lower mini-sternotomy: an approach for treating all valvulopathies?

Ann Thorac Surg

December 2024

Sorbonne University, Department of Cardiovascular and Thoracic Surgery, Institute of Cardiology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Background: Lower mini-sternotomy offers the advantage of providing excellent visualization of the 4 cardiac cavities, allowing surgical treatment of aortic, mitral and tricuspid valves as well as any intra-cavitary procedure. Technical issues, as well as safety and echocardiographic results of this approach, are lacking. The aim of this retrospective study was to describe outcomes of lower mini-sternotomy to treat valvulopathies and other intracardiac surgeries.

View Article and Find Full Text PDF

Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).

J Thorac Oncol

December 2024

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Introduction: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).

Methods: This is a single center, pilot study of patients with clinical stage IA-IIIA NSCLC (AJCC 8th edition) harboring an activating EGFR mutation (Exon 19 deletion, L858R) (NCT04816838).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!